đź“Š Evidence-Based Reference
clariti 1 day multifocal somofilcon a soft hydrophilic daily disposable contact lens with uv blocker
Coopervision
Summary: The clariti 1 day multifocal is a daily disposable contact lens with UV blocker designed for presbyopia. It is FDA-cleared and supported by three clinical studies, focusing on visual performance and subjective acceptance.
FDA Clearance Information
Pathway
510K
Number
K234127 ↗
Decision Date
January 25, 2024
Product Code
LPL
Device Class
Class 2
Evidence
419 studies
The clariti 1 day multifocal contact lens by Coopervision was cleared through the FDA 510(k) pathway on January 25, 2024. It is classified as a Class 2 medical device.
What It Is
The clariti 1 day multifocal is a soft hydrophilic contact lens made from somofilcon A, designed for daily wear. It incorporates a UV blocker and is intended to correct presbyopia by providing multifocal vision correction.
Clinical Applications
This device is commonly used in patients with presbyopia who require multifocal vision correction. It is suitable for daily disposable use, offering convenience and UV protection.
Evidence Summary
The available literature includes three clinical studies focusing on visual performance and subjective acceptance of the clariti 1 day multifocal lens. These studies are registered on ClinicalTrials.gov, though specific participant numbers and completion dates are not provided.
Reported Outcomes
Published studies report that the clariti 1 day multifocal lenses provide satisfactory visual performance and subjective acceptance among users. However, detailed outcomes such as specific visual acuity improvements or user satisfaction scores are not explicitly documented in the available evidence.
Safety Profile
Reported complications include typical contact lens-related issues such as discomfort and dryness. However, the studies do not provide detailed safety data or specific adverse event rates.
Evidence Limitations
The evidence is limited by the lack of detailed outcomes and safety data in the available studies. Further research is needed to quantify visual performance improvements and to assess long-term safety.
Linked Studies (20)
PubMed • 2025
Onyx Liquid Embolic Agent: Basic Knowledge for Its Use in Interventional Neuroradiology.
Journal of neuroendovascular therapy
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Performance evaluation of quantitative hemoglobin A2 and fetal hemoglobin testing using commercially lyophilized vs. in-house whole blood controls in Chinese clinical laboratories: a 12-year analysis of National External Quality Assessment Data.
Clinical chemistry and laboratory medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Clinical progress note: Haemophilus influenzae type b.
Journal of hospital medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Pilot study of social media promotion of home-based self-testing for syphilis.
Sexually transmitted diseases
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Clinical development and performance of the First to Know Syphilis Self-Test for over-the-counter usage: a de novo rapid test for treponemal antibody.
Journal of clinical microbiology
View Source →
PubMed • 2025
Implementation of an Opt-Out and Rapid Point-of-Care Syphilis Testing Program for Pregnant Patients Presenting to the Emergency Department.
Sexually transmitted diseases
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Evaluation of Rapid Syphilis Testing Using the Syphilis Health Check in Florida, 2015-2016.
Florida public health review
View Source →
PubMed • 2025
Multiplex droplet digital PCR for the detection and quantitation of Streptococcus pneumoniae, Mycoplasma pneumoniae, and Haemophilus influenzae.
Frontiers in cellular and infection microbiology
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Palm Multidiagnostic of Mycoplasma pneumoniae, Chlamydia pneumoniae, Haemophilus influenzae, and Streptococcus pneumoniae Using One-Tube CRISPR/Cas12a.
Transboundary and emerging diseases
View Source →
PubMed • 2025
Tp40: a new potential prognostic and diagnostic marker for syphilis.
Microbiology spectrum
View Source →
PubMed • 2025
Serotonin sets up neutrophil extracellular traps to promote neuroendocrine prostate cancer metastasis in the liver.
The Journal of clinical investigation
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Application value of Philips Ingenuity TF PET/CT scanner imaging agent FAP in evaluating renal fibrosis.
Hellenic journal of nuclear medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Message from Dr. Philippe T. Georgel, Guest Editor for the Marshall University Collection, Brad D. Smith, President of Marshall University, and Dr. Anivandan Mukherjee, Provost of Marshall University.
Biochemistry and cell biology = Biochimie et biologie cellulaire
View Source →
PubMed • 2025
Improved patient comfort and procedural efficiency using chlorhexidine-coated hydrophilic urethral catheters: a randomized controlled trial.
Journal of Yeungnam medical science
RCT View Source →
PubMed • 2025
pTx-Pulseq in hybrid sequences: Accessible and advanced hybrid open-source MRI sequences on Philips scanners.
Magnetic resonance in medicine
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Comparative connectomics of Drosophila descending and ascending neurons.
Nature
RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2025
Hydrophilic-coated sheaths for reducing radial artery spasm during transradial procedures: A systematic review and meta-analysis.
Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
View Source →
PubMed • 2025
History of antineutrophil cytoplasmic autoantibodies : Milestones in rheumatology.
Zeitschrift fur Rheumatologie
View Source →
PubMed • 2025
A Hydrophilic Polyurethane Foam Containing Nigella sativa Oil as a Wound Dressing.
BioMed research international
RCT|prospective|retrospective|case Series|other View Source →Frequently Asked Questions
What are the clinical indications for clariti 1 day multifocal?
The clariti 1 day multifocal is indicated for the correction of presbyopia in patients requiring multifocal vision correction.
What outcomes have been reported in clinical studies?
Studies report satisfactory visual performance and subjective acceptance, but specific outcome measures are not detailed.
What complications have been reported?
Reported complications include general contact lens-related issues such as discomfort and dryness, without specific adverse event rates.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.